Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer - Abstract

Aim: This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel.

Patients & Methods: Patients were enrolled from March 2011 to December 2011 in an international expanded access program. In January 2012, when cabazitaxel became commercially available, a prospective study was initiated at University Federico II of Naples and at Rionero in Vulture Hospital.

Results: Forty-seven patients were enrolled in this study. Patients received a median of nine cycles of cabazitaxel. Median progression-free survival was 7.0 months (95% CI: 5.7-8.0). Seventeen patients were still alive at the time of the analysis, with a median overall survival of 14 months (95% CI: 11-16). At multivariate analysis, a higher Gleason score (≥8) appeared to be associated with prolonged progression-free survival (hazard ratio: 0.36; 95% CI: 0.18-0.72); however, the higher Gleason score showed no statistical impact on overall survival.

Conclusion: We hypothesize that the Gleason score has the potential to be incorporated in the clinical decision-making process for definition of treatment strategy in docetaxel-pretreated castration-resistant prostate cancer patients. We encourage further experimentation in this setting.

Written by:
Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, PerdonĂ  S, Palmieri G, De Placido S, Di Lorenzo G.   Are you the author?
Genitourinary Cancer Section, Medical Oncology Division, Department of Endocrinology & Oncology, University Federico II, Napoli, Italy.

Reference: Future Oncol. 2013 Jun;9(6):889-97.
doi: 10.2217/fon.13.39

PubMed Abstract
PMID: 23718309